Analysts project orforglipron sales could reach significant figures in the coming decade, with retatrutide generating substantial revenue in the same timeframe [3]
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S
Patients should inform their healthcare providers about any kidney disease, significant weight changes, or other medications they are taking, as these factors may influence both the therapeutic effects and elimination timeline of GLP-1 receptor agonists
If you have concerns about the administration process, refer to the instructions that came with the medication or consult with your healthcare provider
however, because of their longer half-life and larger dose range, Semaglutide has demonstrated superior weight reduction effectiveness